Literature DB >> 20005738

The expression of IL-8 and IL-8 receptors in pancreatic adenocarcinomas and pancreatic neuroendocrine tumours.

Farah Hussain1, Jayson Wang, Raida Ahmed, Stephanie K Guest, Eric W-F Lam, Gordon Stamp, Mona El-Bahrawy.   

Abstract

BACKGROUND: Inflammatory mediators influence tumour progression. IL-8 has been shown to have pro-angiogenic, mitogenic and motogenic effects and several studies have demonstrated the expression of IL-8 by various human pancreatic cancer cell lines.
METHODS: The expression of IL-8 and IL-8 receptors was studied in 52 pancreatic adenocarcinomas and 52 pancreatic neuroendocrine tumours using immunohistochemistry. The expression of IL-8 and IL-8 receptors was also assessed in eight pancreatic adenocarcinomas and seven neuroendocrine tumours in comparison to normal pancreatic tissue using real time quantitative PCR (qRT-PCR).
RESULTS: Immunohistochemical analysis of the expression of IL-8, IL-8RA and IL-8RB in 52 pancreatic adenocarcinomas demonstrated expression in 25%, 75% and 79% of pancreatic adenocarcinomas, respectively. There was no statistically significant correlation between expression and tumour grade and stage for any of the three antigens. IL-8, IL-8RA and IL-8RB expression was detected in 21%, 63% and 92% of 52 pancreatic neuroendocrine tumours. There was no statistically significant correlation between expression and tumour grade for any of the three antigens. Using qRT-PCR, the expression of each of IL-8, IL-8RA and IL-8RB mRNA was increased in 75% of pancreatic adenocarcinomas. IL-8, IL-8RA and IL-8RB mRNA expression was also increased in 57%, 43% and 29% of pancreatic neuroendocrine tumours. Quantitatively, there was a significant increase in expression level of IL-8 in tumours of both types in comparison to normal pancreatic tissue (38.5-fold in adenocarcinomas and 43.9-fold in neuroendocrine tumours). There was also increased expression of IL-8RA in both tumour types, with higher levels in adenocarcinomas, 2.7-fold and neuroendocrine tumours, 1.7-fold. IL-8RB was slightly increased in adenocarcinomas in comparison to normal pancreas (1.4-fold), but the expression was decreased in neuroendocrine tumours compared with normal pancreas (0.9-fold).
CONCLUSION: This is the first study to show that IL-8 and IL-8 receptors are upregulated in both pancreatic adenocarcinomas and neuroendocrine tumours, and indicate this signalling pathway may modulate tumour behaviour through autocrine and/or paracrine loops. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20005738     DOI: 10.1016/j.cyto.2009.11.010

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  20 in total

Review 1.  Chemokines, chemokine receptors and the gastrointestinal system.

Authors:  Hiroshi Miyazaki; Kazuaki Takabe; W Andrew Yeudall
Journal:  World J Gastroenterol       Date:  2013-05-21       Impact factor: 5.742

Review 2.  Pancreatic neuroendocrine tumors: A review of serum biomarkers, staging, and management.

Authors:  Zu-Yi Ma; Yuan-Feng Gong; Hong-Kai Zhuang; Zi-Xuan Zhou; Shan-Zhou Huang; Yi-Ping Zou; Bo-Wen Huang; Zhong-Hai Sun; Chuan-Zhao Zhang; Yun-Qiang Tang; Bao-Hua Hou
Journal:  World J Gastroenterol       Date:  2020-05-21       Impact factor: 5.742

3.  CXCR2 macromolecular complex in pancreatic cancer: a potential therapeutic target in tumor growth.

Authors:  Shuo Wang; Yanning Wu; Yuning Hou; Xiaoqing Guan; Marcello P Castelvetere; Jacob J Oblak; Sanjeev Banerjee; Theresa M Filtz; Fazlul H Sarkar; Xuequn Chen; Bhanu P Jena; Chunying Li
Journal:  Transl Oncol       Date:  2013-04-01       Impact factor: 4.243

4.  Expression of CXCR2 and its clinical significance in human colorectal cancer.

Authors:  Wenjuan Wu; Changjiang Sun; Daoliang Xu; Xizhi Zhang; Weigan Shen; Ye Lv; Tao Ma
Journal:  Int J Clin Exp Med       Date:  2015-04-15

Review 5.  Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook.

Authors:  Joaquin Mateo; John V Heymach; Amado J Zurita
Journal:  Mol Diagn Ther       Date:  2012-06-01       Impact factor: 4.074

Review 6.  Could signal transducer and activator of transcription 3 be a therapeutic target in obesity-related gastrointestinal malignancy?

Authors:  Katie E O'Sullivan; John V Reynolds; Ciara O'Hanlon; Jacintha N O'Sullivan; Joanne Lysaght
Journal:  J Gastrointest Cancer       Date:  2014-03

7.  Desmoplastic Crosstalk in Pancreatic Ductal Adenocarcinoma Is Reflected by Different Responses of Panc-1, MIAPaCa-2, PaTu-8902, and CAPAN-2 Cell Lines to Cancer-associated/Normal Fibroblasts.

Authors:  Štepán Novák; Michal Kolář; Arpád Szabó; Zdena Vernerová; Lukáš Lacina; Hynek Strnad; Jana Šáchová; Miluše Hradilová; Jan Havránek; Michal Španko; Matúš Čoma; Lukáš Urban; Miriam Kaňuchová; Nikola Melegová; Robert Gürlich; Josef Dvořák; Karel Smetana; Peter Gál; Pavol Szabo
Journal:  Cancer Genomics Proteomics       Date:  2021 May-Jun       Impact factor: 4.069

8.  CpG-island methylation study of liver fluke-related cholangiocarcinoma.

Authors:  R Sriraksa; C Zeller; M A El-Bahrawy; W Dai; J Daduang; P Jearanaikoon; S Chau-In; R Brown; T Limpaiboon
Journal:  Br J Cancer       Date:  2011-03-29       Impact factor: 7.640

9.  Antitumor effect of water decoctions of taxus cuspidate on pancreatic cancer.

Authors:  Chao Qu; Zhen Chen
Journal:  Evid Based Complement Alternat Med       Date:  2014-02-25       Impact factor: 2.629

Review 10.  Molecular mechanism underlying lymphatic metastasis in pancreatic cancer.

Authors:  Zhiwen Xiao; Guopei Luo; Chen Liu; Chuntao Wu; Liang Liu; Zuqiang Liu; Quanxing Ni; Jiang Long; Xianjun Yu
Journal:  Biomed Res Int       Date:  2014-01-22       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.